兆科眼科(6622.HK)午后一度涨超13%，现涨9.09%报1.44港元，总市值7.864亿港元。兆科眼科宣布与AFT Pharmaceuticals Limited签订了BRIMOCHOLPF的分销及供应协议。该产品旨在矫正因老花眼导致的近距离视力丧失，具有潜在的市场前景。兆科眼科与Tenpoint Therapeutics Ltd.建立了合作关系，后者最近公布了BRIO-II试验的积极结果，成功达到了主要研究终点，这为2025年上半年在美国提交新药申请奠定了基础。根据协议，兆科眼科将授予AFT在澳大利亚和新西兰的独家进口、分销、推广、营销及销售权。AFT将为兆科眼科取得相关的当地药物注册，并且兆科眼科将收取一笔不可退还的预付款，后续还可根据达成的里程碑获得额外付款。该协议的签署标志着兆科眼科在国际市场上的进一步拓展，尤其是在老花眼治疗领域的商业化进程中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.